Lionel is a Partner with Earlybird Venture Capital and a Managing Director with Bay City Capital. Lionel contributes a wealth of know-how in the biotechnology, medtech, diagnostic, R&D tools and service fields.

Prior to joining The Pritzker Organization in 2000, Lionel was a principal at Oracle Partners, a healthcare hedge fund. He also held several positions in the industry, including Product Manager at Eli Lilly as well as several sales and marketing positions at Sanofi. Lionel was also a strategy and management consultant to the healthcare industry while at Booz Allen & Hamilton and Accenture Strategic Services. Lionel’s investment activities focus on medical-device companies, biotechnology, as well as diagnostic and specialty pharmaceuticals.

Lionel is a member of the Board of Directors of iQone Healthcare, Oculis SA and iStar Medical. Previously he had board roles with Madrigal Pharmaceuticals (NASDAQ: MDGL), Reliant Pharmaceuticals, Merus N.V. (NASDAQ: MRUS), Interleukin Genetics (NASDAQ: ILIU), Pathway Diagnostics, BioSeek, Nexus Dx, and Nabsys.

Lionel holds an MBA with Distinction from INSEAD and an M.Sc. in Molecular Biology from the University of Geneva.